COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,241 Articles (22,733 medRxiv, 8,508 bioRxiv)

Most recent first Previous |  Page 681: Articles 6801-6810  | Next

Antibody Response Following COVID-19 Boosters During the Omicron Wave in the United States: A Decentralized, Digital Health, Real-World Study
Doornek, T., Shao, N., Burton, P., Ceddia, F., Fraile, B.
10.1101/2022.07.31.22278173 — Posted: 2022-08-02
cardiovascular safety of COVID-19 vaccines in real-world studies: a systematic review and meta-analysis
Chang, Y., Lv, G., Liu, C., Luo, B., Huang, E.
10.1101/2022.08.01.22278252 — Posted: 2022-08-02
H172Y mutation perturbs the S1 pocket and nirmatrelvir binding of SARS CoV-2 main protease through a nonnative hydrogen bond
de Oliveira, V. M., Ibrahim, M. F., Sun, X., Hilgenfeld, R., Shen, J.
10.1101/2022.07.31.502215 — Posted: 2022-08-01
Free energy perturbation calculations of mutation effects on SARS-CoV-2 RBD::ACE2 binding affinity
Sergeeva, A. P., Katsamba, P. S., Sampson, J. M., Bahna, F., Mannepalli, S., Morano, N. C., Shapiro, L., Friesner, R. A., Honig, B.
10.1101/2022.08.01.502301 — Posted: 2022-08-01
SARS-CoV-2-specific CD4+ and CD8+ T cell responses can originate from cross-reactive CMV-specific T cells
Pothast, C. R., Dijkland, R. C., Thaler, M., Hagedoorn, R. S., Kester, M. G., Wouters, A. K., Hiemstra, P. S., van Hemert, M. J., Gras, S., Falkenburg, J. F., Heemskerk, M. H.
10.1101/2022.07.31.502203 — Posted: 2022-08-01
Use of a Self-Care and Educational Mobile App to Improve Outcomes of Patients with Acute Decompensated Heart Failure during the COVID-19 Pandemic
essa, h. a., Jackson, C., Nyjo, S., Kelly, A., Murphy, N., Hartshorne-Evans, N., Walker, L., Oguguo, E., Douglas, H., Sankaranarayanan, R.
10.1101/2022.07.28.22270513 — Posted: 2022-08-01
InterClone: Store, Search and Cluster Adaptive Immune Receptor Repertoires
Wilamowski, J., Xu, Z., Ismanto, H. S., Li, S., Teraguchi, S., Covarrubias, M. A. L., Lu, X., Yamasaki, S., Standley, D. M.
10.1101/2022.07.31.501809 — Posted: 2022-08-01
Recombinant Human ACE2-Fc : A promising therapy for SARS-CoV2 infection
P.K, S., Shandil, R. K., Suresh, P., Biswas, K., Rudramurthy, G. R., Nanjegowda, N. C., Kumaraswamy, B., Battula, N. P., Chowdhury, S. D., Sinha, S., Dutta, S., Dhar, S. K., Narayanan, S., Das, M.
10.1101/2022.07.30.501940 — Posted: 2022-08-01
Epitranscriptomic N6-methyladenosine profile of SARS-CoV-2-infected human lung epithelial cells
Phillips, S., Khadka, S., Bohan, D., Espada, C. E., Maury, W., Wu, L.
10.1101/2022.08.01.502311 — Posted: 2022-08-01
SARS-CoV-2 ORF8 is a viral cytokine regulating immune responses
Kohyama, M., Suzuki, T., Nakai, W., Ono, C., Matsuoka, S., Iwatani, K., Liu, Y., Sakai, Y., Nakagawa, A., Tomii, K., Ohmura, K., Okada, M., Matsuura, Y., Oshima, S., Maeda, Y., Okamoto, T., Arase, H.
10.1101/2022.08.01.502275 — Posted: 2022-08-01

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).